tirzepatide for obesity fda approval Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly GROUNDBREAKING UPDATE! FDA has approved

This keeps it safe from the light in your fridge

Glucagon-like peptide-1 receptor agonists might be disease-modifying in patients with knee osteoarthritis and type 2 diabetes if treatment is sustained for a sufficient period, according to data

This ensures sterility, potency, and regulatory compliance

This investment is one of the most significant milestones for Corxel since its founding as it not only fuels our effort to accelerate the global development of industry-leading therapies against cardiometabolic diseases but also propels the company to a new orbit of growth. Sandy Mou, CEO of Corxel, said at the time